TITLE:
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

CONDITION:
Multiple Sclerosis, Relapsing-Remitting

INTERVENTION:
Natalizumab

SUMMARY:

      The purpose of this study is to determine if natalizumab in combination with AVONEX is safe
      and effective in delaying progression of individuals diagnosed with relapsing remitting
      Multiple Sclerosis (MS).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 55 Years
Criteria:

        Inclusion Criteria:

          -  Diagnosis of MS as defined by McDonald et al, criteria, # 1- 4

          -  Between the ages of 18 and 55, inclusive

          -  Baseline EDSS score between 0.0 and 5.0, inclusive

          -  Have been treated with Avonex for at least the 12 months prior to randomization

          -  Have experienced at least one relapse (while on Avonex) within the 12 months prior to
             randomization.

          -  Cranial MRI scan demonstrating lesions consistent with MS.

          -  Have given written informed consent to participate in the study.

        Exclusion Criteria:

          -  Primary progressive, secondary progressive, or progressive relapsing MS.

          -  MS relapse has occurred within 50 days of randomization

          -  A clinically significant infectious illness within 30 days prior to randomization

          -  History of, or abnormal lab result, indicative of significant disease, that in the
             opinion of the investigator, would preclude the administration of a recombinant
             humanized antibody immunomodulating agent or Avonex for 116 weeks.

          -  History of severe allergic or anaphylactic reactions or known drug hypersensitivity.

          -  Unable to perform the Timed 25-Foot Walk, 9HPT and PASAT 3

          -  Abnormal blood tests at Screening Visit
      
